Published in Drug Week, July 16th, 2004
In one study, data suggest that Avandia may delay and prevent progression to type 2 diabetes and premature cardiovascular disease, specifically in African-American patients with impaired glucose tolerance (IGT), commonly referred to as prediabetes.
In a separate study of African-American and Hispanic-American patients with type 2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.